---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-059298"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2021-12-03T23:59:59+00:00"
generated_at: "2026-06-28T03:52:11.468425+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# AbCellera appoints Neil Aubuchon as Chief Commercial Officer

## Summary
- Neil Aubuchon named CCO effective December 2, 2021; will lead commercial strategy and partnership evaluation.
- Aubuchon brings over 20 years experience from Amgen, Lilly, and Santen, including global marketing roles.
- CEO Carl Hansen cited Aubuchon's commercial experience as key to expanding AbCellera's deal structures.

## SEC filing metadata
- accession: 0001564590-21-059298
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2021-12-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/0001564590-21-059298-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459021059298/abcl-8k_20211202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-059298
- JSON: https://secwatch.observer/filing/0001564590-21-059298.json
- Plain text: https://secwatch.observer/filing/0001564590-21-059298.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.